glp-1 and protein intake Nutrition-First Support for Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance Taking a GLP-1 medication? We've

To ensure the identification of all potentially relevant studies, reference lists of included publications were manually scrutinized

The speed of the development pipeline only adds to the challenge as GLP1 therapies are being used for approved indications beyond diabetes and obesity, including heart, liver and renal disease. With these evolving usage patterns, plan sponsors face a coverage dilemma defined by constant change and escalating financial exposure

Together, these data, most of which do not stem from GLP-1 RA specific research, suggest that beyond biological rebound, integrating body image work, stress regulation, and support for reconstructing identity and agency may be relevant to long-term maintenance

In the STEP 1 trial of 1,961 adults with overweight or obesity, once-weekly semaglutide led to an average weight loss of about 14.9% of body weight over 68 weeks, against 2.4% for placebo

Domestic technology review of microneedle patents